



CRYSPFORMA

SALTS & CO-CRYSTALS



CRYSPFORMA offers systematic salt & co-crystal screening studies to discover and select the salt derivative or co-crystal of an API with optimal solid state properties.

- ▶ **Salts:** Preparation of a salt is the classical strategy to optimize the solid state properties of an active pharmaceutical ingredient. Salt derivatives can improve crystallinity, solubility and stability of a pharmaceutical compound, and are often chosen instead of the free acid or base.
- ▶ **Pharmaceutical co-crystals:** In recent years, the development of a pharmaceutical co-crystal has become a novel strategy to improve the solid state properties of an API. Co-crystals are an alternative to salts when these do not have the appropriate solid state properties or cannot be formed due to the absence of ionizable sites in the API.

TYPE OF STUDIES

- ▶ Salt and co-crystal screening of pharmaceutical ingredients with selected counterions or co-crystal formers.
- ▶ Characterization of crystalline salts and pharmaceutical co-crystals.
- ▶ Development of reliable preparation procedures.
- ▶ Scale-up of the selected salt or pharmaceutical co-crystal.
- ▶ Polymorphism study of the selected salt or co-crystal.
- ▶ Resolution of chiral compounds through selective diastereomeric salt crystallization.

METHODOLOGY

The unit has developed its own salt and co-crystal screening methodology based in the use of selected crystallization procedures in an optimized group of crystallization solvents. The methodology allows performing 1000 crystallization experiments from 10 g of starting API under controlled conditions. We use small scale high throughput crystallization systems controlled by highly skilled scientists to maximise the information drawn from each experiment.

Av. Països Catalans 16
43007 Tarragona (Spain)
Phone: +34 977 920 200
Fax: +34 977 920 224
crysforma@iciq.es
www.crysforma.com